Canada: IP Monitor - No Harm, No Foul: Establish Irreparable Harm Clearly When Seeking Interlocutory Injunctions

Federal Court denies interlocutory injunction for moving party's failure to provide sufficiently clear evidence that it would suffer irreparable harm if the injunction was not issued.

A recent case before the Federal Court, The Regents of the University of California et al v I-Med Pharma Inc1, reaffirmed that in order to establish irreparable harm when seeking an interlocutory injunction in the context of an action for patent infringement, sufficiently clear evidence demonstrating irreparable harm was necessary. In denying the motion for interlocutory injunction, Justice Manson made several interesting observations about the arguments presented by the moving party. Justice Manson also ordered the Plaintiffs to post security for costs.

The Plaintiff and moving party, TearLab Corporation (TearLab), is an exclusive licensee of Canadian Patent No. 2,494,540 (the '540 Patent), which is owned by the other Plaintiff in this case, the Regents of the University of California (University). The '540 Patent generally relates to diagnostic devices, systems, and methods for measuring the osmolarity of tears, said to be useful for diagnosing and treating dry eye disease.

TearLab sought an interlocutory injunction to prevent the Defendant, I-MED Pharma Inc (I-MED), from selling its ophthalmic medical device pending determination at trial on the issues of patent infringement and validity.
I-MED sought security for costs for defending the present interlocutory motion and the patent infringement action as neither TearLab nor the University are ordinarily resident in Canada.

Interlocutory injunction

The three-part test for an interlocutory injunction as outlined by the Supreme Court of Canada2 requires that TearLab establish:

1. a serious issue to be tried;

2. that it will suffer irreparable harm if the injunction is not granted; and

3. that the balance of convenience favours the granting of an injunction.

The Federal Court did not grant TearLab an interlocutory injunction. Justice Manson held that TearLab did not provide sufficiently clear evidence that it would suffer unquantifiable and irreparable harm if the injunction was not issued. TearLab presented four arguments, but was unsuccessful on all four fronts.

Harm to TearLab's goodwill and reputation

TearLab argued that I-MED's product might be inferior to TearLab's product, thereby causing irreparable harm by turning ophthalmologists off of TearLab's technology. Justice Manson ruled that the evidence in support of this argument was speculative and unclear, especially since I-MED's device was approved by Health Canada.

Loss of market opportunity

TearLab also argued that without an interlocutory injunction, it would suffer permanent loss of market share, loss of opportunity to increase its market share, and permanent damage to its goodwill and reputation. Again, Justice Manson held that this argument was unsubstantiated as TearLab's evidence was speculative. Justice Manson noted that TearLab relied heavily on American Cyanamid v Ethicon Ltd3, a 1975 House of Lords decision. While Justice Manson acknowledged that this decision was relevant, it did not trump more recent and relevant decisions of Canadian Courts.

Inability to quantify damages

TearLab argued that irreparable harm ensued from the impossibility of calculating lost sales, as there was no reasonable methodology available to quantify the Defendant's activities. I-MED's expert testified that either (i) an epidemiological model or (ii) a quantitative statistical model could be used to estimate damages.

TearLab's expert argued that the epidemiological model was not viable as additional data, research, and analysis were required to predict damages using the model. Justice Manson held that the non-viability of the epidemiological model was immaterial, as it could be used to calculate reasonable damages if no injunction were granted following trial.

TearLab's expert also criticized the statistical model proposed by I-MED's expert on the basis that future prediction based on TearLab's historical sales data was impossible. TearLab's expert argued that incomplete data, market complexities, and interrelated variables rendered the predicted damages by the statistical model inadequate. Justice Manson found that the evidence submitted by TearLab's expert was insufficient to constitute "clear and not speculative" evidence that actual unquantifiable harm would occur. Furthermore, Justice Manson held that after trial, there were ways of quantifying actual losses in monetary terms even if no injunction were granted. The incomplete information before I-MED's expert at this time would no longer be hypothetical after trial. Data from any intervening and unexpected future events could be incorporated into the statistical model to adjust the projection of losses. Justice Manson stated that "[t]heoretical complexity in calculation is not alone clear evidence that damages are not capable of reasonable quantification".4

Moreover, in rejecting TearLab's claim that its losses were unquantifiable, Justice Manson accepted I-MED's argument that TearLab's position was inconsistent. TearLab argued that, because of the unique nature of the market, its losses could not be quantified if an injunction were refused and it prevailed at trial. Yet, TearLab offered an undertaking to compensate I-MED for I-MED's losses if an injunction were granted and TearLab lost at trial. If I-MED's damages could be quantified if an interlocutory injunction were granted and I-MED prevailed at trial, he saw no reason why TearLab's damages could not be quantified in the opposite scenario.

Ability to pay damages was not properly before the Court

TearLab attempted to argue that I-MED would be unable to pay a monetary award after trial, notwithstanding that it neither alleged, nor led evidence on, this issue. TearLab served a direction to attend on an affiant from the Defendant, requiring him to bring voluminous financial information to his cross-examination. No such documents were produced. Justice Manson refused to draw an adverse inference as the issue was not pleaded in the motion or addressed in the evidence.

Security for costs

I-MED brought a motion for security for costs. Justice Manson followed a trend that requires substantial security to be posted in stages and ordered TearLab (which has virtually no assets in Canada) to post $100,000 through the discovery process with I-MED entitled to seek additional security later in the proceedings.

This decision by the Federal Court reaffirms that it is generally difficult for a moving party seeking an interlocutory injunction to sufficiently and clearly establish that it will experience irreparable harm if the injunction is not granted.

TearLab has appealed the decision.

Link to decision:

2016 FC 606


1 2016 FC 606.

2 RJR-MacDonald Inc v Canada (Attorney General), [1994] 1 SCR 311 at 347-349.

3 [1975] RPC 13 at 542.

4 The Regents of the University of California et al v I-Med Pharma Inc, 2016 FC 606 at para 70.

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.